首页|阿托伐他汀与曲美他嗪联合治疗冠心病的临床效果分析

阿托伐他汀与曲美他嗪联合治疗冠心病的临床效果分析

扫码查看
目的 本研究针对冠心病患者使用阿托伐他汀、曲美他嗪联合治疗,并对疗效做出分析.方法 60 例冠心病患者,通过随机抽样法分为常规组、研究组,各 30 例.常规组采用曲美他嗪治疗,研究组采用阿托伐他汀+曲美他嗪治疗.比较两组患者的疗效、血脂指标、内皮功能指标、心功能指标、心绞痛发作情况.结果 研究组总有效率为 90.00%,高于常规组的 66.67%,差异性具有统计学价值(P<0.05).治疗后,研究组总胆固醇(3.73±0.05)mmol/L、甘油三酯(1.05±0.14)mmol/L、低密度脂蛋白胆固醇(1.16±0.20)mmol/L低于常规组的(5.18±0.66)、(1.88±0.36)、(3.37±0.95)mmol/L,高密度脂蛋白胆固醇(1.88±0.36)mmol/L高于常规组的(1.04±0.11)mmol/L,差异性具有统计学价值(P<0.05).治疗后,研究组一氧化氮(396.87±67.86)μg/L高于常规组的(310.13±50.88)μg/L,内皮素-1(50.05±2.02)μg/L、外周血循环内皮微颗粒(854.67±261.37)×106/L低于常规组的(87.76±4.28)μg/L、(1073.18±212.54)×106/L,差异性具有统计学价值(P<0.05).治疗后,研究组左心室射血分数(52.28±2.84)%高于常规组的(40.80±2.56)%,左心室收缩末期内径(38.03±2.05)mm、左心室舒张末期内径(50.05±2.42)mm小于常规组的(58.78±3.36)、(66.68±4.18)mm,差异性具有统计学价值(P<0.05).治疗后,研究组心绞痛持续时间(3.84±0.74)min/次短于常规组的(7.21±1.91)min/次、发作次数(2.72±0.44)次/周少于常规组的(4.73±0.74)次/周、疼痛程度评分(2.34±0.24)分低于常规组的(4.17±0.51)分,差异性具有统计学价值(P<0.05).结论 冠心病患者使用阿托伐他汀+曲美他嗪联合治疗后,其心功能明显好转,心绞痛发作次数明显减少,可减轻患者疼痛程度,疗效显著,临床应用价值较高.
Clinical effect analysis of atorvastatin combined with trimetazidine in the treatment of coronary heart disease
Objective To analyze the efficacy of atorvastatin combined with trimetazidine in the treatment of patients with coronary heart disease.Methods 60 patients with coronary heart disease were divided into a conventional group and a study group by random sampling method,each with 30 cases.The conventional group was treated with trimetazidine,and the study group was treated with atorvastatin+trimetazidine.The therapeutic effect,blood lipid index,endothelial function index,cardiac function index and attack of angina pectoris were compared between the two groups.Results The total effective rate of the study group was 90.00%,which was higher than 66.67% of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the study group had total cholesterol of(3.73±0.05)mmol/L,triglyceride of(1.05±0.14)mmol/L and low density lipoprotein cholesterol of(1.16±0.20)mmol/L,which were lower than(5.18±0.66),(1.88±0.36)and(3.37±0.95)mmol/L in the conventional group;the high density lipoprotein cholesterol of(1.88±0.36)mmol/L in the study group was higher than(1.04±0.11)mmol/L in the conventional group;the difference was statistically significant(P<0.05).After treatment,the nitric oxide of(396.87±67.86)μg/L in the study group was higher than(310.13±50.88)μg/L in the conventional group;the study group had endothelin-1 of(50.05±2.02)μg/L and peripheral circulating endothelial microparticle of(854.67±261.37)×106/L,which were lower than(87.76±4.28)μg/L and(1073.18±212.54)×106/L in the conventional group;the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction of(52.28±2.84)% in the study group was higher than(40.80±2.56)% in the conventional group;the study group had left ventricular end-systolic diameter of(38.03±2.05)mm and left ventricular end-diastolic diameter of(50.05±2.42)mm,which were smaller than(58.78±3.36)and(66.68±4.18)mm in the conventional group;the difference was statistically significant(P<0.05).After treatment,the duration of angina pectoris of(3.84±0.74)min/time in the study group was shorter than(7.21±1.91)min/time in the conventional group,and the frequency of angina pectoris of(2.72±0.44)times/week was less than(4.73±0.74)times/week in the conventional group;the pain degree score of(2.34±0.24)points in the study group was lower than(4.17±0.51)points in the conventional group;the difference was statistically significant(P<0.05).Conclusion The combined treatment of atorvastatin and trimetazidine shows significant curative effect on patients with coronary heart disease,the cardiac function is significantly improved,the frequency of angina pectoris is significantly reduced,and the pain degree of patients is reduced.This method contains high clinical application value.

AtorvastatinTrimetazidineCombination therapyCoronary heart disease

孙立华

展开 >

252400 莘县燕塔街道社区卫生服务中心

阿托伐他汀 曲美他嗪 联合治疗 冠心病

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(18)